|1.||Goldenberg, David M: 30 articles (01/2015 - 02/2002)|
|2.||Schlom, Jeffrey: 28 articles (11/2015 - 01/2002)|
|3.||Hodge, James W: 17 articles (10/2015 - 09/2002)|
|4.||Sharkey, Robert M: 17 articles (01/2015 - 05/2002)|
|5.||Lin, Jen-Kou: 16 articles (07/2015 - 01/2002)|
|6.||Shively, John E: 15 articles (11/2015 - 12/2003)|
|7.||Wang, Huann-Sheng: 15 articles (07/2015 - 01/2002)|
|8.||Yang, Shung-Haur: 15 articles (07/2015 - 01/2002)|
|9.||Lin, Tzu-Chen: 14 articles (07/2015 - 01/2002)|
|10.||Chen, Wei-Shone: 14 articles (07/2015 - 03/2002)|
01/01/2013 - "In the past, several factors, such as an advanced primary T stage, the primary N+ status, a large tumor size, multiple tumors, a disease-free interval of <12 months, an elevated carcinoembryonic antigen level, the presence of an extrahepatic disease, and the margin width (<1 cm) and status (positive), have been recognized to predict poor outcomes, but most of them lack the sensitivity for accurate individual prognostication. "
06/01/2012 - "In this particular system targeting carcinoembryonic antigen, a small-molecule-binding affinity of 400 pmol/L was sufficient to achieve maximal tumor targeting, and an improvement in affinity to 10 pmol/L showed no significant improvement in tumor uptake at 24 hours postinjection. "
02/01/2008 - "Using nodal status of the primary tumor, disease-free interval, size of the largest metastatic tumor, preoperative carcinoembryonic antigen, bilateral resection, extensive resection (lobectomy or more), gender, number of hepatic tumors, primary cancer site (colon vs. rectum), and age, the nomogram achieved a concordance index of 0.61, statistically significantly greater than chance. "
02/01/2014 - "Immunogenicity and therapeutic efficacy of a dual-component genetic cancer vaccine cotargeting carcinoembryonic antigen and HER2/neu in preclinical models."
05/01/2014 - "At one year, all patients older than 73 years of age with T2-4 tumors and abnormal carcinoembryonic antigen levels benefited, whereas at five years, all had relative reduction in mortality with the largest benefit amongst elderly, highest T-stage patients. "
|2.||Neoplasm Metastasis (Metastasis)
03/01/1995 - "Patients with a normal carcinoembryonic antigen level (</=3 mm/liter), those without bone metastases, older women, and those with a long disease-free interval were most likely to benefit from treatment. "
07/01/1991 - "Age of patient, site of primary, disease-free interval between treatment of primary and of hepatic metastases, preoperative carcinoembryonic antigen levels, and number of metastases, did not relate to prognosis, while sex (P = 0.024), stage of primary (P = 0.026), extent of liver involvement (P less than 0.001), distribution of metastases (P = 0.01) and type of surgery (P = 0.028) significantly affected prognosis as single factors. "
07/01/1979 - "Unfortunately, carcinoembryonic antigen levels are a far more sensitive indicator of hepatic metastases, the group usually not helped by operation. "
12/01/2007 - "Following resection favourable prognostic factors include a long disease-free interval, small number and small size of metastases, a normal carcinoembryonic antigen level, and an absence of concomitant liver metastases and mediastinal lymph node spread. "
05/01/2005 - "On univariate analysis, number of metastases greater than two (P = .0005), extrahepatic disease (P = .0054), disease-free interval less than 12 months (P = .006), carcinoembryonic antigen level greater than 200 ng/mL (P = .0071), and positive hTERT nucleolar staining (P < .0001) were associated with decreased survival. "
|3.||Colorectal Neoplasms (Colorectal Cancer)
01/01/1996 - "The usefulness of postoperative carcinoembryonic antigen (CEA) monitoring and improvements in imaging techniques have renewed enthusiasm for second-look operations (SLO) as the most effective treatment for recurrent colorectal cancer by reresection following early detection. "
06/01/1985 - "The evaluation of serial plasma carcinoembryonic antigen (CEA) levels is one of the most important parameter used to establish the prognosis of surgically cured colorectal cancer patients. "
06/01/1997 - "In this paper, a reference change limit of 2.0 microg/l was estimated for carcinoembryonic antigen in patients with complete remission of colorectal cancer. "
09/01/2012 - "To evaluate the efficacy of (18)F-FDG PET-CT in the diagnosis of recurrence of colorectal cancer (CRC) in patients with elevated values of carcinoembryonic antigen (CEA) and/or signs of recurrence in the multidetector CT (MDCT), and to demonstrate that good results can be obtained applying the ALARA principles. "
01/15/1992 - "Plasma carcinoembryonic antigen levels also decreased significantly (greater than 25%) in 7 of the 14 (50%) patients with colorectal cancer. "
04/01/2011 - "Authors of the current study demonstrate that (125)I-radiolabeled monoclonal antibody, 35A7, which recognizes anti-carcinoembryonic antigen, can be used effectively and safely with low toxicity in the therapy of small volume peritoneal carcinomatosis after cytoreductive surgery."
09/01/1988 - "Improved specificity of the CA 125 enzyme immunoassay for ovarian carcinomas by use of the ratio of CA 125 to carcinoembryonic antigen."
07/01/2001 - "Of the five cases in the immunohistochemical study, three cases with an undifferentiated carcinoma component showed negative staining reactions for PSA and all cases were positive for carcinoembryonic antigen. "
07/01/1998 - "This study is the first to examine the relative and absolute costs of physician examination, carcinoembryonic antigen (CEA) assessment, chest x-ray, and colonoscopy in detecting recurrent disease in patients who have undergone surgical resection for primary colon carcinoma. "
05/01/1998 - "Tissue carcinoembryonic antigen and oestrogen receptor status in breast carcinoma: an immunohistochemical study of clinical outcome in a series of 252 patients with long-term follow-up."
09/01/1991 - "Serum carcinoembryonic antigen measurements occasionally may be useful in the management of certain prostate adenocarcinoma patients."
06/28/2006 - "To evaluate the efficacy of postoperative serial assay of carcinoembryonic antigen (CEA) and cytokeratins for the detection of recurrent disease in patients with colorectal adenocarcinoma after radical surgery. "
10/01/2014 - "The aim of this study was to predict EGFR mutation status in patients with pulmonary adenocarcinoma based on (18)F-fluorodeoxyglucose (FDG) uptake and imaging features in positron emission tomography/computed tomography (PET/CT), as well as on the serum carcinoembryonic antigen (CEA) level. "
03/01/2009 - "The aim of this study was to predict the postoperative prognosis in patients with small-sized pulmonary adenocarcinoma on the basis of FDG uptake on PET, the extent of ground-glass opacity (GGO) on CT, and serum carcinoembryonic antigen (CEA) levels. "
12/01/2005 - "The aim of the study was to define the utility of a limited immunohistochemical panel consisting of CDX-2, cytokeratins 7 (CK7) and 20 (CK20), and carcinoembryonic antigen (CEA) in differentiating primary from secondary bladder adenocarcinomas. "
|3.||Biological Tumor Markers (Tumor Markers)
|6.||Phosphopyruvate Hydratase (Enolase)
|7.||Biological Markers (Surrogate Marker)
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)